Aravax
Melbourne
About Aravax
Aravax is an early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy. The company is using their proprietary technology to reset the immune system to tolerate peanut without evoking allergic reactions during treatment. Aravax was founded in May 2015 through acquisition of intellectual property developed by Alfred Health and Monash University. Aravax has its headquarters in Melbourne, Australia.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $42.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2024)
- Website: aravax.com.au
- Phone: +610396570700
Industries & Categories
Biotechnology, Health Care, Wellness
Social Profiles
Canonical: https://fsome.com/organization/aravax-13361 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.